There was a total of 27 adverse events reported of the 170 patients who received administration of G-CSF; 6 patients had fever, 5 patients had bone pain, 5 patients had a urinary tract infection (UTI), in 2 patients the adverse event was not specified, 1 patient had muscle pain, 1 patient had headache, 1 patient had transient itching/skin rash, 1 patient had left upper quadrant pain (LUQ), 1 patient had pneumonia, 1 patient had transient hepatic dysfunction, and 1 patient had hepatopathy. This evidence concerns the gene CSF3 and susceptibility to pneumonia measurement.